Health Tech Tino Delamerced STAT Plus: He had an M.D. and a Ph.D. but didn’t match into a residency. It was the push he needed to jump into health tech
Business Andrew Joseph ‘We are not casting a wide enough net’: Rob Perez on how biopharma companies can help out their neighbors
Heavyweights Isabella Cueto ‘Where the bats hung out’: How a basement hideaway at UC Berkeley nurtured a generation of blind innovators
A STAT Investigation Megan Molteni and Mario Aguilar STAT Plus: Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment
Health Amy Sokolow With science and scripture, a Baltimore pastor is fighting Covid-19 vaccine skepticism
Heavyweights Sharon Begley ‘I really don’t know what happened to Jim’: Friends ask where James Watson’s odious attitudes about race came from
Health Usha Lee McFarling A doctor’s humbling journey treating long Covid: ‘The second we think we know what we are doing, we fall flat on our face’
In the Lab Akila Muthukumar From the Navy to a neuroscience lab: how a daughter’s diagnosis spurred her mother’s career shift
In the Lab Megan Molteni CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade
In the Lab Isabella Cueto Hundreds of families share a lethal inheritance. This kidney researcher hopes to break the chain
Health Isabella Cueto ‘We don’t have a say’: Siobhan Wescott wants to elevate the voices of Native Americans in public health
Health Usha Lee McFarling STAT Plus: She was told ‘girls don’t do that.’ Now Margaret-Mary Wilson is a top executive at UnitedHealth Group
Heavyweights Isabella Cueto Denizens of ‘The Cave’ became changemakers and leaders. Here are some of its notable alumni
Exclusive Erin Brodwin STAT Plus: In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’
Health Andrew Joseph Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
Health Tech Casey Ross STAT Plus: Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money
Heavyweights Lev Facher STAT Plus: Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science
Heavyweights Nicholas Florko STAT Plus: A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust
Heavyweights Usha Lee McFarling A ‘duty to warn’: An ER doctor, shaped by war and hardship, chronicles the searing realities of Covid-19
Heavyweights Eric Boodman As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival
In the Lab Alex Hogan, Hyacinth Empinado and Crystal Milner Watch: How did you get your start in science? And other questions with the STAT Wunderkinds
Heavyweights Shraddha Chakradhar At the top of her field, a Covid-19 researcher fights back against a different kind of virus: sexism and power imbalances in science
Health Gabrielle Glaser Inequality ‘surrounds you’: A Black doctor returns to hard-hit Louisiana after treating and contracting Covid-19 in New York
Health Natalya Ortolano ‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community
Exclusive Nicholas Florko and Matthew Herper STAT Plus: Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?
Health Andrew Joseph ‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response
Health Andrew Joseph After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?
Politics STAT Staff STAT Plus: Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation
Health Tech Megan Thielking STAT Plus: A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation
Biotech Nicholas Florko STAT Plus: The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025
Heavyweights Lev Facher How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda